OBJECTIVE: To describe characteristics of older adults who received opioids for chronic non-cancer pain (CP), ascertain types of opioid treatments received, and examine associations between patient characteristics and treatment outcomes. DESIGN: Retrospective cohort study. SETTING: Primary care practice in New York City. PATIENTS: Eligible patients were >or=65 and newly started on an opioid for CP. OUTCOME MEASURES: Patient characteristics and provider treatments, as well as duration of opioid therapy, proportion discontinuing therapy, and evidence of pain reduction and continued use of opioid for more than 1 year. Other outcomes included the presence and type(s) of side effects, abuse/misuse behaviors, and adverse events. RESULTS: Participants (N = 133) had a mean age of 82 (range = 65-105), were mostly female (84%), and white (74%). Common indications for opioid treatment included back pain (37%) and osteoarthritis (35%). Mean duration of opioid use was 388 days (range = 0-1,880). Short-acting analgesics were most commonly prescribed. Physicians recorded side effects in 40% of cases. Opioids were discontinued in 48% of cases, mostly due to side effects/lack of efficacy. Pain reduction was documented in 66% of patient records, while 32% reported less pain and continued treatment for >or=1 year. Three percent displayed abuse/misuse behaviors, and 5% were hospitalized due to opioid-related adverse events. CONCLUSIONS: Over 50% of older patients with CP tolerated treatment. Treatment was discontinued in 48% of cases, mostly due to side effects and lack of analgesic efficacy. Efforts are needed to establish the long-term safety and efficacy of opioid treatment for CP in diverse older patient populations.
OBJECTIVE: To describe characteristics of older adults who received opioids for chronic non-cancer pain (CP), ascertain types of opioid treatments received, and examine associations between patient characteristics and treatment outcomes. DESIGN: Retrospective cohort study. SETTING: Primary care practice in New York City. PATIENTS: Eligible patients were >or=65 and newly started on an opioid for CP. OUTCOME MEASURES: Patient characteristics and provider treatments, as well as duration of opioid therapy, proportion discontinuing therapy, and evidence of pain reduction and continued use of opioid for more than 1 year. Other outcomes included the presence and type(s) of side effects, abuse/misuse behaviors, and adverse events. RESULTS:Participants (N = 133) had a mean age of 82 (range = 65-105), were mostly female (84%), and white (74%). Common indications for opioid treatment included back pain (37%) and osteoarthritis (35%). Mean duration of opioid use was 388 days (range = 0-1,880). Short-acting analgesics were most commonly prescribed. Physicians recorded side effects in 40% of cases. Opioids were discontinued in 48% of cases, mostly due to side effects/lack of efficacy. Pain reduction was documented in 66% of patient records, while 32% reported less pain and continued treatment for >or=1 year. Three percent displayed abuse/misuse behaviors, and 5% were hospitalized due to opioid-related adverse events. CONCLUSIONS: Over 50% of older patients with CP tolerated treatment. Treatment was discontinued in 48% of cases, mostly due to side effects and lack of analgesic efficacy. Efforts are needed to establish the long-term safety and efficacy of opioid treatment for CP in diverse older patient populations.
Authors: Judy T Zerzan; Nancy E Morden; Stephen Soumerai; Dennis Ross-Degnan; Elizabeth Roughead; Fang Zhang; Linda Simoni-Wastila; Sean D Sullivan Journal: Med Care Date: 2006-11 Impact factor: 2.983
Authors: Bridget A Martell; Patrick G O'Connor; Robert D Kerns; William C Becker; Knashawn H Morales; Thomas R Kosten; David A Fiellin Journal: Ann Intern Med Date: 2007-01-16 Impact factor: 25.391
Authors: Stephen F Butler; Simon H Budman; Kathrine C Fernandez; Brian Houle; Christine Benoit; Nathaniel Katz; Robert N Jamison Journal: Pain Date: 2007-05-09 Impact factor: 6.961
Authors: Daniel H Solomon; Jerry Avorn; Philip S Wang; George Vaillant; Danielle Cabral; Helen Mogun; Til Stürmer Journal: Arthritis Rheum Date: 2006-02-15
Authors: Krista L Lentine; Ngan N Lam; Huiling Xiao; Janet E Tuttle-Newhall; David Axelrod; Daniel C Brennan; Vikas R Dharnidharka; Hui Yuan; Mustafa Nazzal; Jie Zheng; Mark A Schnitzler Journal: Am J Nephrol Date: 2015-03-27 Impact factor: 3.754
Authors: A Carmona-Bayonas; P Jiménez-Fonseca; E Castañón; A Ramchandani-Vaswani; R Sánchez-Bayona; A Custodio; D Calvo-Temprano; J A Virizuela Journal: Clin Transl Oncol Date: 2016-07-21 Impact factor: 3.405
Authors: Krista L Lentine; Ngan N Lam; Mark A Schnitzler; Amit X Garg; Huiling Xiao; Sheila E Leander; Daniel C Brennan; Sandra J Taler; David Axelrod; Dorry L Segev Journal: Clin Transplant Date: 2015-09-18 Impact factor: 2.863